Massachusetts’ top health official predicts that coverage for GLP-1 weight-loss medications will return in just a few years. Commercial insurers and state agencies had dropped these benefits due to high costs, but an anticipated “price crash” could lead to renewed coverage.

A new Sunlight.com survey shows that 41% of GLP-1 users credit career advancement to their weight loss. Respondents report gaining confidence, experiencing improved workplace treatment, and even securing raises and promotions.

Viking Therapeutics’ experimental pill helped patients lose 12.2 % of their body weight in just 13 weeks—better than Eli Lilly’s latest effort but still shy of Novo Nordisk’s own results. Yet it was Novo Nordisk’s shares that “popped,” underscoring how the race for obesity drugs can move markets in unexpected ways.